Prolight Diagnostics advanced its Psyros POC system toward commercialization in 2024, supported by positive preclinical data, new patents, and SEK 22.4 million in warrant funding, but remains pre-revenue and dependent on a critical rights issue for continued operations.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.